Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A Study of ZN-c5 in Subjects With Breast Cancer

Multiple Cancer Types

This is a Phase 1 / 2, open-label, multicenter, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZN-c5 administered orally in subjects with advanced estrogen receptor positive, human epidermal growth factor receptor 2 negative (ER+ / HER2-) breast cancer. ZN-c5 will be evaluated both as monotherapy and in combination with palbociclib (IBRANCEĀ®).
Breast, Phase I
Abramson, Vandana

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: